HDAC inhibition ameliorates cone survival in retinitis pigmentosa mice.
Marijana SamardzijaAndrea CornaRaquel Gomez-SintesMohamed Ali JarbouiAngela ArmentoJerome E RogerEleni PetridouWadood HaqFrancois Paquet-DurandEberhart ZrennerPedro de la VillaGünther ZeckChristian GrimmPatricia BoyaMarius UeffingDragana TrifunovićPublished in: Cell death and differentiation (2020)
Cone photoreceptor cell death in inherited retinal diseases, such as Retinitis Pigmentosa (RP), leads to the loss of high acuity and color vision and, ultimately to blindness. In RP, a vast number of mutations perturb the structure and function of rod photoreceptors, while cones remain initially unaffected. Extensive rod loss in advanced stages of the disease triggers cone death by a mechanism that is still largely unknown. Here, we show that secondary cone cell death in animal models for RP is associated with increased activity of histone deacetylates (HDACs). A single intravitreal injection of an HDAC inhibitor at late stages of the disease, when the majority of rods have already degenerated, was sufficient to delay cone death and support long-term cone survival in two mouse models for RP, affected by mutations in the phosphodiesterase 6b gene. Moreover, the surviving cones remained light-sensitive, leading to an improvement in visual function. RNA-seq analysis of protected cones demonstrated that HDAC inhibition initiated multi-level protection via regulation of different pro-survival pathways, including MAPK, PI3K-Akt, and autophagy. This study suggests a unique opportunity for targeted pharmacological protection of secondary dying cones by HDAC inhibition and creates hope to maintain vision in RP patients even in advanced disease stages.
Keyphrases
- cell death
- pi k akt
- signaling pathway
- rna seq
- cell cycle arrest
- histone deacetylase
- single cell
- end stage renal disease
- mouse model
- ejection fraction
- cell proliferation
- diabetic retinopathy
- oxidative stress
- chronic kidney disease
- dna methylation
- palliative care
- optical coherence tomography
- copy number
- genome wide
- cancer therapy
- skeletal muscle